USPTO serial 90726883
KINTOR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 12, 2022
- Examiner
- NITKIN, DINISHA F
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KINTOR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SUZHOU KINTOR PHARMACEUTICALS, INC.
SUZHOU CITY, JIANGSU PROVINCE, CN
Other trademarks owned by SUZHOU KINTOR PHARMACEUTICALS, INC.
Suzhou, CN
Suzhou, CN
Suzhou, CN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alex Patel
Alex Patel Patel IP, P.C.20700 Ventura Blvd., Suite 235Woodland Hills, CA 91364United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for treatment of cancer; sachets for pharmaceutical purposes, medicines in the form of capsules, chemico-pharmaceutical preparations, drugs for medical purposes, chemical preparations for pharmaceutical purposes, biological preparations for medical purposes, chemical preparations for medical purposes, all of the foregoing for the treatment of cancer; anti-cancer pharmaceutical preparations; pharmaceutical preparations for the diagnosis and treatment of cancer; pharmaceutical products for the prevention, diagnosis, treatment and adjunctive therapy of cancer, cardiovascular disease, nervous system diseases, infectious diseases, respiratory diseases, endocrine and metabolic diseases, mental disorder, skin disease, diseases of the blood system, digestive system diseases, immune system diseases, diseases of genitourinary system, ocular diseases, otolaryngology and dentistry diseases, musculoskeletal and connective tissue diseases, nutritional diseases, diseases caused by external factors, namely, poisoning and injury; compounds for treating cancer; pharmaceuticals, medical and veterinary preparations for the prevention, diagnosis, treatment and adjunctive therapy of cancer, cardiovascular disease, nervous system diseases, infectious diseases, respiratory diseases, endocrine and metabolic diseases, mental disorder, skin disease, diseases of the blood system, digestive system diseases, immune system diseases, diseases of genitourinary system, ocular diseases, otolaryngology and dentistry diseases, musculoskeletal and connective tissue diseases, nutritional diseases, diseases caused by external factors, namely, poisoning and injury; sanitary preparations for medical purposes; dietetic food and substances, namely, dietetic foods, sugar substitutes, nutritional beverages, and dietary supplements for weight loss adapted for medical and veterinary use; food for babies; dietary supplements for humans and animals; plasters and materials, namely, gauze for medical dressings; materials for dental fillings and for sealing purposes; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; pharmaceutical preparations for the prevention, diagnosis, treatment and adjunctive therapy of coronaviruses, Covid-19, influenza viruses, influenza A, influenza B, SARS-CoV-1, SARSCoV-2, MERS-CoV, and rhinoviruses | ACTIVE | — |
| 042 | Scientific and medical research services; pharmaceutical research services; research relating to pharmaceuticals; research and development of pharmaceutical products; biotechnology research; biochemistry and chemical research services; scientific research relating to biology and chemistry; scientific research in the field of pharmacy; scientific research into the development of new products; testing services for assessing the efficacy and safety of pharmaceuticals; preparation of reports relating to scientific research; analytical medical and scientific laboratory services; medical and scientific laboratory research and analysis; development of products; development of pharmaceutical preparations for the diagnosis and treatment of cancer; advisory services relating to scientific research; scientific and technological services in the field of pharmaceuticals and research and design relating thereto, namely, consulting and advisory services, CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services; industrial analysis and research services in the field of pharmaceuticals; design and development of computer hardware and software; information, advisory and consultancy services relating to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SUZHOU KINTOR PHARMACEUTICALS, INC.
- Other trademarks owned by Kintor Pharmaceutical Limited
- Other trademarks owned by Kintor Pharmaceutical Limited
- Other trademarks owned by Kintor Pharmaceutical Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named KINTOR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 7, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Apr 23, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 23, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 23, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 23, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 23, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 12, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 12, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 4, 2022 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Apr 26, 2022 | ISPO | WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST | — |
| Apr 26, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 26, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 19, 2022 | APET | ASSIGNED TO PETITION STAFF | — |
| Apr 7, 2022 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Apr 6, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 23, 2022 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 22, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 15, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 15, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 14, 2022 | ALIE | ASSIGNED TO LIE | — |
| Mar 12, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 20, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 20, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 20, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 20, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 20, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 20, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 28, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 28, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 28, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 18, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 25, 2021 | NWAP | NEW APPLICATION ENTERED | — |